# Portfolio Score: Ketamine - Meditation Journey Music Mobile App

**Idea**: A mobile app providing guided ketamine-assisted meditation journeys, targeting tech leaders experiencing burnout and isolation.  
**Target Niche**: Individuals exploring ketamine-assisted therapy and meditation practices  
**Initial JTBD**: To find a solution that helps alleviate burnout, enhance professional creativity, and provide a sense of personal rejuvenation through a guided ketamine-assisted meditation journey.  
**Buyer**: "Optimized CTO" — typically a CTO or startup founder in high-stakes environments seeking productivity, resilience, and leadership enhancement.  
**Budgeted Buyer**: ❌ (Uncertain budget authority and size)  
**Recurring Job**: ✅ (Ongoing need for stress relief and rejuvenation)

## Scoring

### 1. Desirability Signal Strength

**Score: 2/5** (Weak)

**Validation Tests**:
- Social Narrative Test
- Fake Door Test
- Landing/Waitlist Test
- DM Outreach Test
- Concierge MVP Test
- Prepayment/Preorder Test

**Assess current status**: Not run yet

**Demand Signals**:
- Waitlists: None yet
- Pre-orders: None yet
- DMs/Inquiries: None yet
- Repeat usage: None yet
- Emotional attachment: None yet

**Confidence**: Low

### 2. Niche Durability Score

**Score: 3/5** (Moderate)

**Growth Trajectory**:
- Psychedelic therapy market is emerging but uncertain due to regulatory factors.
- Niche sustainability is moderate; depends on legal acceptance and adoption rates.

**Budgeted Buyer**:
- Economic buyer is not well-defined.
- Unclear budget authority and size.
- Budget stability is uncertain due to niche market.

**Recurring Job**:
- Frequency: Weekly/Monthly
- Job recurrence: Ongoing
- Job importance: Important for mental health
- Job durability: Likely to exist for 12-36 months depending on regulatory environment

**Confidence**: Medium

### 3. Moat Potential

**Score: 2/5** (Weak)

**Data Moat Potential**:
- Proprietary data opportunities are limited.
- No clear compounding mechanism or data uniqueness.

**Workflow Lock-In Potential**:
- Limited integration depth and dependency.
- Weak workflow lock-in strength.

**Switching Costs Potential**:
- Minimal migration pain.
- No significant saved state or team habits.

**Overall Moat Potential**: Weak

**Confidence**: Low

### 4. Expansion Revenue Depth

**Score: 2/5** (Weak)

**Expansion Revenue Levers**:
- Lever 1: Additional therapy types
  - **Type**: Product expansion
  - **Potential**: Moderate
  - **Expansion multiple**: 1.5-2x
  - **Timeline**: 12-24 months

- Lever 2: Corporate wellness solutions
  - **Type**: B2B expansion
  - **Potential**: Moderate
  - **Expansion multiple**: 2-3x
  - **Timeline**: 18-36 months

**Value Metric**: Subscription growth

**Expansion Path**:
- Initial revenue: Low
- Expansion path: Diversify offerings and target broader markets
- Target expansion: Moderate
- Expansion timeline: 12-36 months

**Confidence**: Low

### 5. JTBD Frequency Map

**Score: 3/5** (Moderate)

**Job Frequency**: Weekly/Monthly

**Job Triggers**:
- **Time-based**: Weekly stress cycles
- **Event-based**: Burnout episodes
- **Action-based**: Seeking mental health support

**Frequency Increase Factors**:
- Success factors: Effective stress relief
- Growth factors: Wider acceptance of psychedelic therapy
- Value factors: Proven benefits
- Dependency factors: Integration into lifestyle

**Frequency Boosters**: Increased awareness and acceptance of psychedelic therapy

**Confidence**: Medium

### 6. Wave/Timing Analysis

**Score: 2/5** (Weak)

**Wave Maturity Assessment**:
- **Wave stage**: Emerging
- **Wave timing**: Early
- **Wave sustainability**: Medium

**Early Indicators Track**:
- Growth signals: Moderate
- Decline signals: High regulatory risks
- Signal strength: Weak

**Competitor Velocity Mapping**:
- Competitor speed: Moderate
- Competitor activity: High
- Market dynamics: Uncertain

**Regulatory Horizon Scan**:
- **Regulatory opportunities**: Limited
- **Regulatory risks**: High (CRITICAL for ketamine)
- **Regulatory timing**: Uncertain

**Confidence**: Low

### 7. Implementation Cost + Risk

**Score: 2/5** (High cost/risk)

**Implementation Cost**:
- **Time estimate**: 12-24 months
- **Resource estimate**: High (development, legal, marketing)
- **Complexity**: High
- **Infrastructure needs**: Significant (legal, tech, safety measures)

**Risk Level**:
- **Demand risk**: High
- **Moat risk**: High
- **Market risk**: High
- **Team risk**: Medium
- **Technical risk**: Medium
- **Regulatory risk**: High (CRITICAL for ketamine)

**Combined Score**: 2/5

**Confidence**: Low

### 8. Expected Value (EV) Model

**Probability of Success**:
- **Demand validation probability**: 40%
- **Moat/MRR validation probability**: 30%
- **Build success probability**: 50%
- **Market success probability**: 30%
- **Regulatory success probability**: 20% (CRITICAL for ketamine)
- **Overall probability**: 30%

**Impact (MRR Potential)**:
- **Year 1 MRR potential**: Low
- **Year 2 MRR potential**: Moderate
- **Year 3 MRR potential**: Moderate
- **Lifetime value**: Moderate per user

**Expected Value Calculation**:
- **EV = 30% × [Year 2 MRR] = Low**
- **EV Score**: Low

**Confidence**: Low

## Portfolio Score Summary

| Criterion                | Score | Weight | Weighted |
|--------------------------|-------|--------|----------|
| Desirability Signal      | 2/5   | 1.0    | 2.0      |
| Niche Durability         | 3/5   | 1.0    | 3.0      |
| Moat Potential           | 2/5   | 1.0    | 2.0      |
| Expansion Revenue        | 2/5   | 1.0    | 2.0      |
| JTBD Frequency           | 3/5   | 1.0    | 3.0      |
| Wave/Timing              | 2/5   | 1.0    | 2.0      |
| Cost (inverse)           | 2/5   | 1.0    | 2.0      |
| Risk (inverse)           | 2/5   | 1.0    | 2.0      |
| **Total Score**          | **18/40** |      | **18.0** |

**Portfolio Priority**: ⭐⭐ Low Priority (15-19)

## Recommendation

### Verdict: ⚠️ PIVOT

**Rationale**:
- High regulatory risks and safety concerns associated with ketamine.
- Weak moat potential and high implementation costs.
- Low confidence in niche durability and market timing.

**Key Factors**:
1. Regulatory uncertainty for ketamine-assisted therapy.
2. High demand and market risks in a niche market.
3. Lack of clear economic buyer and budget authority.
4. High implementation complexity and resource needs.

**Next Steps**:
1. **Immediate**: Re-evaluate the legal and regulatory landscape for ketamine.
2. **Short-term (1-3 months)**: Consider pivoting to a broader wellness or mental health focus.
3. **Long-term (3-12 months)**: Develop partnerships with health and wellness organizations to mitigate risks and expand reach.

**Confidence**: Low